Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 5.70%
As of Monday, November 02, TuHURA Biosciences, Inc.’s HURA share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Commentary & Analysis
Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 7.76%
As of Friday, October 30, TuHURA Biosciences, Inc.’s HURA share price has dipped by 7.76%, which has investors questioning if this is right time to buy.Jenna Brashear
Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 7.10%
As of Wednesday, October 28, TuHURA Biosciences, Inc.’s HURA share price has dipped by 7.10%, which has investors questioning if this is right time to buy.Tudor Pop
Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 5.04%
As of Monday, October 26, TuHURA Biosciences, Inc.’s HURA share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 10.50%
As of Monday, October 26, TuHURA Biosciences, Inc.’s HURA share price has dipped by 10.50%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | HURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $109.6 | $223.5 | 23% |
|
| Shares Out (Mil) | 64.0 | 53.4 | 53% |
|
| Institutional Ownership | 28.3% | 92.9% | 12% |
|
| Float (Mil) | 39.7 | 40.4 | 42% |
|
| Beta | na | 0.96 | na |
|
| Avg Daily Volume (000s) | 581 | 463 | 61% |
|
| Price Change (52-week) |
(30.7%) | 45.9% | 29% |
|
| Growth | HURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | 2 | |
| Current EPS | ($0.153) | ($0.530) | ($0.605) | |
| Month Ago EPS | na | ($0.530) | ($0.605) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | 6.3% | (15.5%) | (189.3%) | |
| Financials | HURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($31) | ($44) | 20% |
|
| EPS (TTM) | ($0.543) | ($1.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($30) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $136 | $173 | 23% |
|
| Valuation | HURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.93 | 2.08 | 84% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (92.3%) | (47.0%) | 6% |
|
| ROE | (163.8%) | (52.7%) | 5% |
|
| Liabilities to Assets | 41.7% | 29.6% | 32% |
|
| F-Score | 1 | 2 | 1% |
|
TuHURA Biosciences, Inc. did not pass any screens on 11/2/2026.
